Banque Pictet & Cie SA lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.4% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,953 shares of the biopharmaceutical company's stock after selling 14,668 shares during the period. Banque Pictet & Cie SA's holdings in Gilead Sciences were worth $4,141,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of GILD. Redwood Financial Network Corp raised its position in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares during the period. Argentarii LLC raised its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 99 shares during the period. Nicolet Advisory Services LLC raised its position in shares of Gilead Sciences by 2.9% during the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 100 shares during the period. Peak Financial Advisors LLC raised its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after purchasing an additional 100 shares during the period. Finally, Perkins Coie Trust Co raised its position in shares of Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
Analyst Upgrades and Downgrades
GILD has been the subject of several research analyst reports. Oppenheimer cut their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.
Check Out Our Latest Report on Gilead Sciences
Insider Transactions at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares of the company's stock, valued at $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,500 shares of company stock worth $6,340,745. Company insiders own 0.27% of the company's stock.
Gilead Sciences Stock Down 3.9%
GILD traded down $4.42 on Friday, hitting $110.13. The company had a trading volume of 3,198,431 shares, compared to its average volume of 7,688,914. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The stock has a market capitalization of $136.99 billion, a price-to-earnings ratio of 23.15, a P/E/G ratio of 0.73 and a beta of 0.29. The stock has a fifty day moving average price of $107.62 and a 200-day moving average price of $104.50. Gilead Sciences, Inc. has a 12-month low of $68.14 and a 12-month high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm earned ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences's payout ratio is currently 66.53%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
